The IPO, with a face worth of Re 1, is totally an offer-for-sale (OFS) as much as 27,644,231 fairness shares by promoters, and investor promoting shareholders. The supply additionally features a subscription reservation with a reduction to eligible staff within the worker reservation portion.
Samara Capital Markets Holding Restricted, Kotak Pre-IPO Alternatives Fund, Plutus Wealth Administration LLP, and Ashish Kacholia are the key shareholders within the firm.
Within the OFS, Shree Hari Belief will offload as much as 2,700,000 fairness shares by Dhirajkumar Savjibhai Vasoya, as much as 12,958,126 fairness shares by Samara Capital Markets Holding Restricted, as much as 2,615,750 fairness shares by Kotak Pre-IPO Alternatives Fund, and as much as 6,670,355 fairness shares by NHPEA Sparkle Holding B.V.
The Supply is being made via the book-building course of, whereby no more than 50% of the supply is allotted to certified institutional patrons, and never lower than 15% and 35% of the supply is assigned to non-institutional and retail particular person bidders respectively.
Sahajanand Medical Applied sciences
Sahajanand Medical Applied sciences is a Class III and Class C/D medical units firm with a portfolio of technologically superior medical units throughout vascular and structural coronary heart intervention.
Sahajanand Medical Applied sciences was based by Dhirajlal Kotadia within the 12 months 2001 and over time, it has launched a number of modern merchandise, pushed by its deal with analysis and growth and precision manufacturing capabilities enabling it to ship high quality merchandise backed by scientific knowledge, with a presence throughout 76 international locations, as of March 31, 2025.
Its portfolio consists of VI merchandise together with coronary intervention merchandise akin to coronary stents and coronary balloons, SH merchandise consists of Trans-Catheter Aortic Valves and Occluders, and different merchandise together with its personal model of renal stents, peripheral drug coated balloons and different buying and selling merchandise.
In keeping with the F&S Report, it’s a main market share within the drug eluting stent (DES) market in India, with a market share of almost 25.00% in CY 2025 of the overall DES gross sales quantity in India.
SMT monetary
SMT Restricted’s income from operations elevated by 13.67% to Rs 1,024.88 crore in Fiscal 2025 from Rs 901.60 crore in Fiscal 2024 primarily on account of a rise within the sale of units pushed by larger gross sales in Europe and the remainder of the world, primarily led by the structural coronary heart vertical. Revenue for the 12 months stood at Rs 25.15 crore in Fiscal 2025 in comparison with a loss after tax of Rs 7.35 crore in Fiscal 2024.
Lead managers
Motilal Oswal Funding Advisors Restricted, Avendus Capital Non-public Restricted, HSBC Securities and Capital Markets (India) Non-public Restricted and Nuvama Wealth Administration Restricted are the book-running lead managers and MUFG Intime India Non-public Restricted is the registrar of the problem.
The fairness shares are proposed to be listed on the Nationwide Inventory Trade of India Restricted and BSE Restricted.
Additionally Learn: SaaS unicorn Amagi Media Labs recordsdata DRHP with Sebi, to lift Rs 1,020 crore from contemporary difficulty
(Disclaimer: Suggestions, recommendations, views and opinions given by the specialists are their very own. These don’t characterize the views of Financial Occasions)
